Evidence map›Paper›PMID 38834767›Full record

ArticleBasic research in cardiology2024

Heart-specific NFAT5 knockout suppresses type I interferon signaling and aggravates coxsackievirus-induced myocarditis.

Guangze Zhao, Huifang M Zhang, Ali Reza Nasseri, Fione Yip, Nikita Telkar, Yankuan T Chen, Sana Aghakeshmiri, Christoph Küper, Wan Lam, Wenli Yang and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Basic research in cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Guangze ZhaoDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-1372-1179
Huifang M ZhangDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
Ali Reza NasseriCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, 1081 Burrard Street, Vancouver, B.C, V6Z 1Y6, Canada.
Fione YipCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, 1081 Burrard Street, Vancouver, B.C, V6Z 1Y6, Canada.
Nikita TelkarBritish Columbia Cancer Research Centre, University of British Columbia, Vancouver, Canada.
Yankuan T ChenCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, 1081 Burrard Street, Vancouver, B.C, V6Z 1Y6, Canada.
Sana AghakeshmiriCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, 1081 Burrard Street, Vancouver, B.C, V6Z 1Y6, Canada.
Christoph KüperMSH Medical School Hamburg, IMM Institute for Molecular Medicine, Medical University, Hamburg, Germany.
Wan LamDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
Wenli YangDepartment of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
James ZhaoCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, 1081 Burrard Street, Vancouver, B.C, V6Z 1Y6, Canada.
Honglin LuoDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. honglin.luo@hli.ubc.ca.
Bruce M McManusDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. bruce.mcmanus@hli.ubc.ca.
Decheng YangDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. decheng.yang@hli.ubc.ca.

Funding

CIHR PJT169202
6 · The paper itself

Abstract

Nuclear factor of activated T cells 5 (NFAT5) is an osmosensitive transcription factor that is well-studied in renal but rarely explored in cardiac diseases. Although the association of Coxsackievirus B3 (CVB3) with viral myocarditis is well-established, the role of NFAT5 in this disease remains largely unexplored. Previous research has demonstrated that NFAT5 restricts CVB3 replication yet is susceptible to cleavage by CVB3 proteases. Using an inducible cardiac-specific Nfat5-knockout mouse model, we uncovered that NFAT5-deficiency exacerbates cardiac pathology, worsens cardiac function, elevates viral load, and reduces survival rates. RNA-seq analysis of CVB3-infected mouse hearts revealed the significant impact of NFAT5-deficiency on gene pathways associated with cytokine signaling and inflammation. Subsequent in vitro and in vivo investigation validated the disruption of the cytokine signaling pathway in response to CVB3 infection, evidenced by reduced expression of key cytokines such as interferon β1 (IFNβ1), C-X-C motif chemokine ligand 10 (CXCL10), interleukin 6 (IL6), among others. Furthermore, NFAT5-deficiency hindered the formation of stress granules, leading to a reduction of important stress granule components, including plakophilin-2, a pivotal protein within the intercalated disc, thereby impacting cardiomyocyte structure and function. These findings unveil a novel mechanism by which NFAT5 inhibits CVB3 replication and pathogenesis through the promotion of antiviral type I interferon signaling and the formation of cytoplasmic stress granules, collectively identifying NFAT5 as a new cardio protective protein.

Indexed as

Coxsackievirus InfectionsDisease Models, AnimalEnterovirus B, HumanInterferon Type IMice, KnockoutMyocarditisSignal TransductionAnimalsCytokinesHumansMaleMiceMice, Inbred C57BLMyocytes, CardiacTranscription FactorsVirus ReplicationCytokinesInterferon Type INfat5 protein, mouseTranscription FactorsCoxsackievirusInterferon betaMyocarditisNFAT5

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.